You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,207,116


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,207,116
Title:Remedies for ischemia
Abstract: The present invention relates to uses and methods of parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), for recruiting stem cells into tissue suffering from ischemia, wherein said stem cells are preferably capable of repairing and/or regenerating said tissue suffering from ischemia. Accordingly, the uses and methods of the present invention are preferably suitable for the prevention and/or treatment of ischemia. Moreover, the present invention relates to a composition comprising parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), and/or G-CSF or a G-CSF fragment for use as a pharmaceutical composition. In a particular aspect, a DPP IV antagonist is applied in the uses, methods and/or compositions of the present invention.
Inventor(s): Franz; Wolfgang M. (Wessling, DE), Theiss; Hans (Munich, DE), Zaruba; Marc-Michael (Donzdorf, DE), Brunner; Stefan (Munich, DE)
Assignee: Ludwig-Maximilians-Universitat Munchen (Munich, DE)
Application Number:12/296,584
Patent Claims:1. A method of repairing and/or regenerating ischemic tissue in a patient in need thereof comprising administering a pharmaceutical composition comprising a peptide comprising amino acids 1-34 of parathyroid hormone (PTH) to a patient in need thereof in an amount which is effective to recruit stem cells into ischemic tissue and repair and/or regenerate said tissue, wherein said pharmaceutical composition is administered at least once daily for at least one day.

2. The method of claim 1, wherein said stem cells are selected from the group consisting of: a) CD34(+)/CD45(+) and CD34(-)/CD45(+) cells, each in combination with the subpopulations CD31 (+), Sca-1 (+) or C-kit(+), b) multipotent adult progenitor cells (MAPC), c) endothelial progenitor cells (EPC) characterized by CD34(+), CD45(+), CD31(+), d) side population cells (SP) and e) lineage-negative stem cells, lin(-), c-kit(+).

3. The method of claim 1, wherein said pharmaceutical composition is administered subcutaneously.

4. The method of claim 1, wherein said ischemia is selected from the group consisting of myocardial ischemia, cerebral ischemia, renal ischemia, liver ischemia, peripheral muscle tissue ischemia, retinal ischemia and spinal cord ischemia.

5. The method of claim 3, wherein said myocardial ischemia is caused by heart failure, hypertension, coronary artery disease (CAD), myocardial infarction, thrombo-embolic events, trauma, surgical and/or interventional measures.

6. The method of claim 5, wherein said surgical or interventional measure is a procedure to regain blood flow selected from the group consisting of thrombolysis, balloon angioplasty, stenting, coronary or peripheral bypass surgery and ventriculo-coronary stenting.

7. The method of claim 1, wherein said pharmaceutical composition further comprises human G-CSF.

8. The method of claim 1, wherein said pharmaceutical composition further comprises a DPP IV antagonist selected from the group consisting of Diprotin A, Vildagliptin and Sitagliptin.

9. The method of claim 1, wherein said ischemia is myocardial ischemia caused by myocardial infarction.

10. A method of repairing and/or regenerating ischemic tissue in a patient in need thereof comprising subcutaneously administering a pharmaceutical composition comprising a peptide comprising amino acids 1-34 of parathyroid hormone (PTH) to a patient in need thereof in an amount which is effective to recruit stem cells into ischemic tissue and repair and/or regenerate said tissue.

11. A method of repairing and/or regenerating ischemic tissue in a patient in need thereof comprising administering a pharmaceutical composition comprising (A) a DPP IV antagonist selected from the group consisting of Diprotin A, Vildagliptin and Sitagliptin and (B) a peptide comprising amino acids 1-34 of parathyroid hormone (PTH) to a patient in need thereof in an amount which is effective to recruit stem cells into ischemic tissue and repair and/or regenerate said tissue.

12. A method of repairing and/or regenerating ischemic tissue in a patient in need thereof comprising administering a pharmaceutical composition comprising a peptide comprising amino acids 1-34 of parathyroid hormone (PTH) to a patient in need thereof in an amount which is effective to recruit stem cells into ischemic tissue and repair and/or regenerate said tissue, wherein said ischemia is myocardial ischemia caused by a surgical and/or interventional measure which is a procedure to regain blood flow selected from the group consisting of thrombolysis, balloon angioplasty, stenting, coronary or peripheral bypass surgery and ventriculo-coronary stenting.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.